Validation of multiparametric approaches for the prediction of sudden cardiac death in patients with Brugada syndrome and electrophysiological study.

INTRODUCTION AND OBJECTIVES: Multiparametric scores have been designed for better risk stratification in Brugada syndrome (BrS). We aimed to validate 3 multiparametric approaches (the Delise score, Sieira score and the Shanghai BrS Score) in a cohort with Brugada syndrome and electrophysiological study (EPS). METHODS: We included patients diagnosed with BrS and previous EPS between 1998 and 2019 in 23 hospitals. C-statistic analysis and Cox proportional hazard regression models were used. RESULTS: A total of 831 patients were included (mean age, 42.8±13.1; 623 [75%] men; 386 [46.5%] had a type 1 electrocardiogram (ECG) pattern, 677 [81.5%] were asymptomatic, and 319 [38.4%] had an implantable cardioverter-defibrillator). During a follow-up of 10.2±4.7 years, 47 (5.7%) experienced a cardiovascular event. In the global cohort, a type 1 ECG and syncope were predictive of arrhythmic events. All risk scores were significantly associated with events. The discriminatory abilities of the 3 scores were modest (particularly when these scores were evaluated in asymptomatic patients). Evaluation of the Delise and Sieira scores with different numbers of extra stimuli (1 or 2 vs 3) did not substantially improve the event prediction c-index. CONCLUSIONS: In BrS, classic risk factors such as ECG pattern and previous syncope predict arrhythmic events. The predictive capabilities of the EPS are affected by the number of extra stimuli required to induce ventricular arrhythmias. Scores combining clinical risk factors with EPS help to identify the populations at highest risk, although their predictive abilities remain modest in the general BrS population and in asymptomatic patients.

Monomorphic ventricular tachycardia in patients with Brugada syndrome: A multicenter retrospective study.

BACKGROUND: Isolated cases of monomorphic ventricular tachycardia (MVT) in patients with Brugada syndrome (BrS) have been reported. OBJECTIVE: We aimed to describe the incidence and characteristics of MVT in a cohort of patients with BrS who had received an implantable cardioverter-defibrillator (ICD). METHODS: Data from 834 patients with BrS implanted with an ICD in 15 tertiary hospitals between 1993 and 2014 were included. RESULTS: The mean age of enrolled patients was 45.3 ± 13.9 years; 200 patients (24%) were women. During a mean follow-up of 69.4 ± 54.3 months, 114 patients (13.7%) experienced at least 1 appropriate ICD intervention, with MVT recorded in 35 patients (4.2%) (sensitive to antitachycardia pacing in 15 [42.8%]). Only QRS width was an independent predictor of MVT in the overall population. Specifically, 6 (17.1%) patients presented with right ventricular outflow tract tachycardia (successfully ablated from the endocardium in 4 and epicardial and endocardial ablation in 1), 2 patients with MVT arising from the left ventricle (1 successfully ablated in the supra lateral mitral annulus), and 2 (5.7%) patients with bundle branch reentry ventricular tachycardia. Significant structural heart disease was ruled out by echocardiography and/or cardiac magnetic resonance imaging. CONCLUSION: In this retrospective study, 4.2% of patients with BrS implanted with an ICD presented with MVT confirmed as arising from the right ventricular outflow tract tachycardia in 6, patients with MVT arising from the left ventricle in 2, and patients with bundle branch reentry ventricular tachycardia in 2. Endocardial and/or epicardial ablation was successful in 80% of these cases. These data imply that the occurrence of MVT should not rule out the possibility of BrS. This finding may also be relevant for ICD model selection and programming.

Experiencia inicial con la extracción de electrodos de marcapasos y desfibrilador asistida con láser excimer / Initial experience with excimer laser-assisted pacemaker and defibrillator lead extraction

La extracción de electrodos de marcapasos y/o desfibriladores de larga evolución puede ser una técnica exigente. Presentamos los resultados de la extracción asistida por láser excimer de los primeros 44 electrodos en 25 pacientes, con una mediana de tiempo de electrodo implantado de 7 (2-20) años. Las indicaciones para la extracción fueron fractura de electrodo en 17 casos, decúbito de bolsa en 4, bacteriemia en 2 y endocarditis sobre electrodo en 2 casos. Se logró la extracción completa de 43 electrodos (97,7%), mientras que en 1 caso se abandonó la porción distal de menos de 4 cm del electrodo. No se produjo mortalidad intrahospitalaria. El láser excimer se presenta como una alternativa segura y eficaz para la extracción de electrodos de marcapasos o desfibrilador, con resultados excelentes en nuestra serie (AU)

Explantation of chronically implanted pacemaker or defibrillator leads can be technically demanding. We present the results of the first 44 leads extracted with excimer laser sheaths in 25 patients with a median lead implantation time of 7 years (range: 2 to 20 years). Indications for extraction were lead fracture in 17 patients, pocket infection in 4, septicemia in 2, and lead endocarditis in 2 cases. Complete extraction was achieved in 43 leads (97.7%), while the lead tip (<4cm) was abandoned in 1 case. There was no in-hospital mortality. The excimer laser-assisted system is a safe and efficient alternative for pacemaker and defibrillator lead extraction. This technology has resulted in excellent outcomes in our series, allowing us to treat remarkably difficult cases (AU)

[Initial experience with excimer laser-assisted pacemaker and defibrillator lead extraction]. / Experiencia inicial con la extracción de electrodos de marcapasos y desfibrilador asistida con láser excimer.

Explantation of chronically implanted pacemaker or defibrillator leads can be technically demanding. We present the results of the first 44 leads extracted with excimer laser sheaths in 25 patients with a median lead implantation time of 7 years (range: 2 to 20 years). Indications for extraction were lead fracture in 17 patients, pocket infection in 4, septicemia in 2, and lead endocarditis in 2 cases. Complete extraction was achieved in 43 leads (97.7%), while the lead tip (< 4 cm) was abandoned in 1 case. There was no in-hospital mortality. The excimer laser-assisted system is a safe and efficient alternative for pacemaker and defibrillator lead extraction. This technology has resulted in excellent outcomes in our series, allowing us to treat remarkably difficult cases.

[Use of anticoagulation at the time of discharge in patients with heart failure and atrial fibrillation]. / Uso de anticoagulación al alta hospitalaria en pacientes con insuficiencia cardíaca y fibrilación auticular.

INTRODUCTION AND OBJECTIVES: To assess the degree of compliance with current guidelines for chronic anticoagulation in patients with heart failure and atrial fibrillation. PATIENTS AND METHOD: From the INCARGAL Study database, we analyzed data from 195 consecutive patients (88 men; mean age 76 10 years) with both conditions, admitted to three Galician hospitals between January and March 1999. It was assumed that these patients should have received anticoagulant therapy at discharge, unless contraindicated. We studied the association of treatment at discharge (anticoagulation or not) with the presence or absence of contraindications. RESULTS: 152 patients (78%) had no contraindication for anticoagulation and 43 had at least one (absolute: 11, relative: 32). Only 50% of patients without contraindications received anticoagulation at the time of discharge. No patient with an absolute contraindication and 3 with a relative one received anticoagulation. Factors related with the less frequent prescription of anticoagulation therapy in patients without a formal contraindication were: age, a previous history of coronary heart disease, absence of valvular heart disease, prior myocardial infarction, treatment with beta-blocking agents, non performance of an echocardiogram, and admission to a department other than cardiology. On multivariate analysis, age, prior myocardial infarction, and non-valvular disease were found to be independent predictors of less use of anticoagulation. CONCLUSIONS: Anticoagulant therapy is used less often than recommended at discharge in patients with heart failure and atrial fibrillation for whom there were no contraindications. Advanced age reduces its use. The presence of other indications for antiplatelet or anticoagulation therapy appears to determine the choice of one or the other. Noncompliance with the guidelines due to overprescription was not found.

Uso de anticoagulación al alta hospitalaria en pacientes con insuficiencia cardíaca y fibrilación auricular / Use of anticoagulation at the time of discharge in patients with heart failure and atrial fibrillation

Introducción y objetivos. Evaluar el grado de cumplimiento de las guías sobre uso de anticoagulación crónica en pacientes con insuficiencia cardíaca y fibrilación auricular. Pacientes y método. Se usó la base de datos del estudio INCARGAL, analizando datos de 195 pacientes consecutivos (88 varones, edad 76 ñ 10 años) admitidos con ambos diagnósticos en tres hospitales gallegos entre enero y junio de 1999. Se asumió que todos deberían de haber recibido anticoagulación al alta hospitalaria en ausencia de contraindicaciones. Se comparó el tratamiento al alta (anticoagulación o no) con la presencia o ausencia de contraindicaciones. Resultados. Un total de 152 pacientes (78 por ciento) no tenían contraindicaciones para la anticoagulación y 43 presentaban alguna (absoluta, 11; relativa, 32). De los pacientes sin contraindicación, sólo recibieron anticoagulación al alta el 50 por ciento. Ningún paciente con contraindicación absoluta y tres con contraindicación relativa recibieron anticoagulación. La prescripción de anticoagulación en los pacientes sin contraindicaciones fue menor en los que tenían una mayor edad, antecedente de cardiopatía isquémica, ausencia de valvulopatía, uso de bloqueadores beta, no realización de ecocardiograma e ingreso en un servicio diferente del de cardiología (p < 0,05). En el análisis multivariante, la edad, el infarto de miocardio previo y la ausencia de valvulopatía significativa permanecieron como predictores independientes de menor uso de anticoagulación. Conclusiones. El empleo de anticoagulación al alta hospitalaria en pacientes sin contraindicación para su uso, con fibrilación auricular e insuficiencia cardíaca, es menor del recomendado. La edad avanzada disminuye su empleo. La presencia de otras indicaciones para la antiagregación o la anticoagulación parecen determinar la elección de una u otra terapia. No hubo mala adecuación por exceso de prescripción (AU)

[Management by hypothermia of junctional ectopic tachycardia appearing after pediatric heart surgery]. / Tratamiento mediante hipotermia de la taquicardia ectópica de una unión tras cirugía cardíaca infantil.

Junctional ectopic tachycardia (JET) is a complication of the repair of congenital cardiac malformations that responds poorly to conventional treatment. We report our experience with the use of moderate hypothermia in its management. Twelve infants with postoperative JET treated with hypothermia were reviewed. The mean interval between the diagnosis of JET and initiation of hypothermia was 1.5 0.5 hours. In the first 24 hours of hypothermia, central temperature and heart rate decreased significantly. Arterial pressure and diuresis tended to increase and central venous pressure tended to decrease. No direct adverse events occurred. All the patients but one survived and are alive and free of neurological deficits after 15 12 months.

Tratamiento mediante hipotermia de la taquicardia ectópica de la unión tras cirugía cardíaca infantil / Management by hypothermia of junctional ectopic tachycardia appearing after pediatric heart surgery

La taquicardia ectópica de la unión (TEU) es una complicación que aparece tras las reparaciones de cardiopatías congénitas, con una escasa respuesta al tratamiento convencional. Describimos nuestra experiencia en el uso de hipotermia moderada como parte de su tratamiento. Se revisaron las historias de 12 pacientes con TEU postoperatoria tratados con hipotermia. El intervalo entre el diagnóstico de TEU y el inicio de la hipotermia fue de 1,5 ñ 0,5 h. Durante las primeras 24 h hubo un descenso significativo de la temperatura y la frecuencia cardíaca, con tendencia al aumento de la presión arterial y de la diuresis y al descenso de la presión venosa central. No hubo complicaciones relacionadas con la hipotermia. Todos excepto un paciente sobrevivieron y tras un seguimiento de 15 ñ 12 meses permanecen vivos y sin secuelas neurológicas (AU)